FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

/in

TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 TARPEYO (developed under the project name NEFECON) is the first and only FDA- approved treatment that was specifically designed for […]

Read more

2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon

/in

Management of Destiny Pharma (DEST), the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their […]

Read more

ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe

/in

New investor, Partners in Equity – joins existing investors Health Innovations, INKEF Capital LSP and Invest-NL Proceeds will be used for commercial European launch of updated Kaleido insulin patch pump system including automated insulin delivery (AID) or closed loop December 16, 2021, Utrecht, The Netherlands – ViCentra, the company behind Kaleido, the world’s smallest and lightest wearable […]

Read more

Depixus Raises USD 35.4M in Series A Financing

/in

The financing will support development of a commercial instrument system based on the company’s proprietary and disruptive MAGNA™ technology. MAGNA™ is set to unlock the field of dynamic genomics. Funds raised from a global investor syndicate led by Lansdowne Partners and Bpifrance and supported by funds bringing additional experience in the life science sector. Paris, […]

Read more

Biocomposites year of international growth and product advancement

/in

Expansion into new geographies and enhanced approval for STIMULAN to treat bacterial infection Keele, UK, 15 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to provide the following business update. Read more…

Read more